trending Market Intelligence /marketintelligence/en/news-insights/trending/AWIOzU-ivxmgjNapC-T0hg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA grants uniQure breakthrough therapy designation for hemophilia drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA grants uniQure breakthrough therapy designation for hemophilia drug

The U.S. FDA granted uniQure NV breakthrough therapy designation for AMT-060, an investigational gene therapy for patients with severe hemophilia B.

Hemophilia B is a serious and rare inherited disease in males characterized by insufficient blood clotting.

The designation is based on the ongoing phase 1 and 2 studies of the drug that show sustained increases in Factor IX, reductions in Factor IX replacement usage and a near cessation of spontaneous bleeding in patients with severe disease at up to 12 months follow-up.